Sumant Lamba, MD
Interventional Cardiology · Jacksonville, FLNPI 1306804687
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,939 of the $25,233 with a category attached, or 63.2%. 52 manufacturers reported payments, led by Abbott at 37.9% of the total. Reporting peaked in 2019 at $11,173 and has fallen 79.9% since, to $2,250 in 2025.
Across 430 payments — averaging $58.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Abiomed$5K
- Cvrx, Inc.$2K
- Medtronic$1K
- Cardiovascular Systems Inc.$1K
- Actelion Pharmaceuticals US, Inc.$938
- plus $6K from 46 others
Across 207 payments — averaging $4040.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$409K
- Amgen$129K
- Abbott$79K
- Boehringer Ingelheim International GmbH$62K
- Medtronic$54K
- Cvrx, Inc.$45K
- plus $58K from 4 others
What the payments were for
- Consulting fees$7,72831%
- Travel & lodging$1,4576%
- Food & beverage$15,93963%
- Education$1090%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$8,891
- Impella$2,775
- Barostim Neo System$979
- Coronary Orbital Atherectomy System$884
- ONYX FRONTIER$294
- CoreValve Evolut$248
- Repatha$222
- Resolute$218
- VERQUVO$204
- FLOWTRIEVER CATHETER, S$202
- CT THROMBECTOMY SYSTEM KIT$202
- Optis Coronary Imaging System$157
- Reveal LINQ$155
- WATCHMAN FLX$143
- Artis icono$134
- TherOx DS2 Console$132
- Catheter$132
- Downstream Cartridge$132
- GENERAL - STENTS$131
- Inspire Upper Airway Stimulation System$126
How this compares
$25,233 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 211 | $298,696 |
| EliquisApixaban | 242 | $247,602 |
| FarxigaDapagliflozin Propanediol | 183 | $215,660 |
| JardianceEmpagliflozin | 141 | $195,629 |
| XareltoRivaroxaban | 40 | $63,566 |
| Repatha SureclickEvolocumab | 16 | $16,195 |
| CorlanorIvabradine Hcl | 20 | $15,668 |
| Repatha PushtronexEvolocumab | 11 | $6,937 |
| Ranolazine ErRanolazine | 38 | $6,666 |
| Metoprolol Succinate | 479 | $5,826 |
| Losartan Potassium | 415 | $3,534 |
| ClopidogrelClopidogrel Bisulfate | 303 | $2,856 |
| Atorvastatin Calcium | 340 | $2,547 |
| Rosuvastatin Calcium | 261 | $2,531 |
| Prasugrel Hcl | 28 | $2,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $384 | $298,696211 claims |
| PfizerEliquis | $270 | $247,602242 claims |
| AstraZenecaFarxiga | $428 | $215,660183 claims |
| Boehringer IngelheimJardiance | $440 | $195,629141 claims |
| Johnson & JohnsonXarelto | $283 | $63,56640 claims |
| AmgenCorlanor | $635 | $15,66820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Jacksonville
- Siddharth WayangankarJacksonville$1.2M
- Dominick AngiolilloJacksonville$387K
- Ruby SatpathyJacksonville$205K
- Bharat GummadiJacksonville$153K
- Raguveer MurthyJacksonville$65K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.